Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo  

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

By  

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes

By  

Letters in Drug Design & Discovery, Vol. 14, Iss. 1, 2017-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

By Montanya Eduard  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1451-1467

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes

By Augustyns Koen   Van der Veken Pieter   Haemers Achiel  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 10, 2005-10 ,pp. : 1387-1407

Informa Healthcare

Access to resources Recommend Favorite